Inflammation serves as a crucial defense mechanism, safeguarding us from infections and injuries. However, when it becomes chronic, it can lead to severe health issues such as arthritis, heart disease, and diabetes. Until recently, the exact process through which the body shifts from an active immune response to a healing state was not well understood.
Fat-Derived Molecules as Immune Regulators
A groundbreaking study published in Nature Communications has revealed that small fat-derived molecules known as epoxy-oxylipins play a vital role in regulating the immune response. These molecules are instrumental in preventing the accumulation of intermediate monocytes, a type of immune cell linked to chronic inflammation and subsequent tissue damage.
To investigate this mechanism, researchers conducted a controlled experiment involving healthy volunteers. Participants received a small injection of UV-killed E. coli bacteria in their forearms, triggering a temporary inflammatory response characterized by pain, redness, heat, and swelling, similar to reactions following an infection or injury.
Volunteers were split into two groups: one receiving preventive treatment and the other therapeutic treatment.
Throughout the study, participants were administered a drug named GSK2256294, which inhibits an enzyme called soluble epoxide hydrolase (sEH). This enzyme typically breaks down epoxy-oxylipins, and blocking it was aimed at enhancing their levels.
In the preventive group, 24 volunteers participated, with half receiving the drug and the other half receiving a placebo two hours prior to the onset of inflammation. The therapeutic group, consisting of another 24 volunteers, received treatment four hours after inflammation began, reflecting a real-world treatment scenario.
Enhancing Protective Lipids to Mitigate Immune Cells
In both groups, the inhibition of sEH led to increased levels of epoxy-oxylipins. Those who received the drug reported faster pain relief and exhibited significantly reduced levels of intermediate monocytes in their blood and tissues. Interestingly, the medication did not significantly alter visible symptoms like redness or swelling.
Further analysis identified a specific epoxy-oxylipin, 12,13-EpOME, which suppresses a protein signaling pathway known as p38 MAPK, responsible for monocyte transformation. Laboratory tests confirmed this mechanism in volunteers who were administered a p38 blocking drug.
Lead author Dr. Olivia Bracken from UCL stated, "Our findings unveil a natural pathway that curbs the expansion of harmful immune cells, facilitating quicker inflammation resolution. Targeting this mechanism could lead to safer therapies that restore immune balance without compromising overall immunity."
Corresponding author Professor Derek Gilroy added, "This study marks the first mapping of epoxy-oxylipin activity in humans during inflammation. By enhancing these protective fat molecules, we could develop safer treatments for diseases driven by chronic inflammation."
Scientists focused on epoxy-oxylipins due to previous animal studies indicating their potential to alleviate inflammation and pain, although their specific role in human biology remained unclear until now.
Future Research Directions for Arthritis and Heart Disease
The study paves the way for clinical trials assessing sEH inhibitors as potential treatments for conditions like rheumatoid arthritis and cardiovascular disease. Dr. Bracken noted that these inhibitors could be tested alongside existing treatments to evaluate their effectiveness in preventing or slowing joint damage associated with rheumatoid arthritis.
Dr. Caroline Aylott from Arthritis UK emphasized the complexity of pain associated with arthritis and the necessity of research that enhances our understanding of pain experiences. She expressed enthusiasm for the study's findings, which could lead to innovative pain management strategies for arthritis patients.
This research was supported by Arthritis UK and involved collaboration from UCL, King's College London, the University of Oxford, Queen Mary University of London, and the National Institute of Environmental Health Sciences in the USA.
Notes
*Intermediate monocytes are white blood cells that assist in fighting infections and repairing tissues. While they play a role in coordinating the immune response, excessive or prolonged presence can lead to chronic inflammation.